select a format

Single User License
USD 2000 INR 128340
Site License
USD 4000 INR 256680
Corporate User License
USD 6000 INR 385020

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Venous Leg Ulcers (Crural ulcer)-Pipeline Review, H2 2015

Venous Leg Ulcers (Crural ulcer)-Pipeline Review, H2 2015


  • Products Id :- GMDHC7000IDB
  • |
  • Pages: 73
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Venous Leg Ulcers (Crural ulcer)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Venous Leg Ulcers (Crural ulcer)-Pipeline Review, H2 2015', provides an overview of the Venous Leg Ulcers (Crural ulcer)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Venous Leg Ulcers (Crural ulcer) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Venous Leg Ulcers (Crural ulcer) Overview 8

Therapeutics Development 9

Pipeline Products for Venous Leg Ulcers (Crural ulcer)-Overview 9

Pipeline Products for Venous Leg Ulcers (Crural ulcer)-Comparative Analysis 10

Venous Leg Ulcers (Crural ulcer)-Therapeutics under Development by Companies 11

Venous Leg Ulcers (Crural ulcer)-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Venous Leg Ulcers (Crural ulcer)-Products under Development by Companies 15

Venous Leg Ulcers (Crural ulcer)-Companies Involved in Therapeutics Development 16

Adocia 16

CardioVascular BioTherapeutics, Inc. 17

CoDa Therapeutics, Inc. 18

CytoTools AG 19

FirstString Research, Inc. 20

Intralytix, Inc. 21

MacroCure Ltd. 22

MediWound Ltd. 23

Pergamum AB 24

RegeneRx Biopharmaceuticals, Inc. 25

Smith & Nephew Plc 26

Stratatech Corporation 27

Venous Leg Ulcers (Crural ulcer)-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

Biochaperone PDGF-BB-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Cathelicidin-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CL-05-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CODA-001-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

CureXcell-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

CVBT-141B-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

EscharEx-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Granexin-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

HP-802247-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

LL-37-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

RGN-137-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

WPP-201-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Venous Leg Ulcers (Crural ulcer)-Recent Pipeline Updates 56

Venous Leg Ulcers (Crural ulcer)-Dormant Projects 63

Venous Leg Ulcers (Crural ulcer)-Discontinued Products 64

Venous Leg Ulcers (Crural ulcer)-Product Development Milestones 65

Featured News & Press Releases 65

Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment 65

Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results 65

Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications 66

Oct 13, 2014: Smith & Nephew announces top-line results of HP802-247 Phase 3 study 66

May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication 67

Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 68

Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers 68

Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet 69

Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers 70

Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers 71

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2015 9

Number of Products under Development for Venous Leg Ulcers (Crural ulcer)-Comparative Analysis, H2 2015 10

Number of Products under Development by Companies, H2 2015 11

Comparative Analysis by Late Stage Development, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 13

Comparative Analysis by Early Stage Development, H2 2015 14

Products under Development by Companies, H2 2015 15

Venous Leg Ulcers (Crural ulcer)-Pipeline by Adocia, H2 2015 16

Venous Leg Ulcers (Crural ulcer)-Pipeline by CardioVascular BioTherapeutics, Inc., H2 2015 17

Venous Leg Ulcers (Crural ulcer)-Pipeline by CoDa Therapeutics, Inc., H2 2015 18

Venous Leg Ulcers (Crural ulcer)-Pipeline by CytoTools AG, H2 2015 19

Venous Leg Ulcers (Crural ulcer)-Pipeline by FirstString Research, Inc., H2 2015 20

Venous Leg Ulcers (Crural ulcer)-Pipeline by Intralytix, Inc., H2 2015 21

Venous Leg Ulcers (Crural ulcer)-Pipeline by MacroCure Ltd., H2 2015 22

Venous Leg Ulcers (Crural ulcer)-Pipeline by MediWound Ltd., H2 2015 23

Venous Leg Ulcers (Crural ulcer)-Pipeline by Pergamum AB, H2 2015 24

Venous Leg Ulcers (Crural ulcer)-Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2015 25

Venous Leg Ulcers (Crural ulcer)-Pipeline by Smith & Nephew Plc, H2 2015 26

Venous Leg Ulcers (Crural ulcer)-Pipeline by Stratatech Corporation, H2 2015 27

Assessment by Monotherapy Products, H2 2015 28

Number of Products by Stage and Target, H2 2015 30

Number of Products by Stage and Mechanism of Action, H2 2015 32

Number of Products by Stage and Route of Administration, H2 2015 34

Number of Products by Stage and Molecule Type, H2 2015 36

Venous Leg Ulcers (Crural ulcer) Therapeutics-Recent Pipeline Updates, H2 2015 56

Venous Leg Ulcers (Crural ulcer)-Dormant Projects, H2 2015 63

Venous Leg Ulcers (Crural ulcer)-Discontinued Products, H2 2015 64

List of Figures

Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H2 2015 9

Number of Products under Development for Venous Leg Ulcers (Crural ulcer)-Comparative Analysis, H2 2015 10

Number of Products under Development by Companies, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 13

Assessment by Monotherapy Products, H2 2015 28

Number of Products by Top 10 Targets, H2 2015 29

Number of Products by Stage and Top 10 Targets, H2 2015 29

Number of Products by Top 10 Mechanism of Actions, H2 2015 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 31

Number of Products by Top 10 Routes of Administration, H2 2015 33

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 33

Number of Products by Top 10 Molecule Types, H2 2015 35

Number of Products by Stage and Top 10 Molecule Types, H2 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adocia

CardioVascular BioTherapeutics, Inc.

CoDa Therapeutics, Inc.

CytoTools AG

FirstString Research, Inc.

Intralytix, Inc.

MacroCure Ltd.

MediWound Ltd.

Pergamum AB

RegeneRx Biopharmaceuticals, Inc.

Smith & Nephew Plc

Stratatech Corporation

Venous Leg Ulcers (Crural ulcer) Therapeutic Products under Development, Key Players in Venous Leg Ulcers (Crural ulcer) Therapeutics, Venous Leg Ulcers (Crural ulcer) Pipeline Overview, Venous Leg Ulcers (Crural ulcer) Pipeline, Venous Leg Ulcers (Crural ulcer) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com